Apis Capital Advisors LLC Makes New Investment in Cellebrite DI Ltd. $CLBT

Key Points

• Apis Capital Advisors LLC has acquired 290,000 shares of Cellebrite DI Ltd. ($CLBT), valued at approximately $5.6 million, making it the firm's 9th biggest holding.
• Several institutional investors have increased their stakes in Cellebrite DI, with Teacher Retirement System of Texas boosting its holdings by 121.3% during the first quarter.
• Wall Street analysts currently rate Cellebrite DI as a "buy," with an average price target of $22.40, despite varying targets set by different firms.

Apis Capital Advisors LLC purchased a new position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 290,000 shares of the company's stock, valued at approximately $5,635,000. Cellebrite DI accounts for 2.7% of Apis Capital Advisors LLC's portfolio, making the stock its 9th biggest position. Apis Capital Advisors LLC owned 0.12% of Cellebrite DI as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of CLBT. Assetmark Inc. purchased a new position in Cellebrite DI during the 1st quarter valued at about $33,000. Catalyst Capital Advisors LLC acquired a new stake in Cellebrite DI during the first quarter worth about $51,000. Virtus Advisers LLC acquired a new stake in shares of Cellebrite DI during the first quarter valued at about $63,000. Gen Wealth Partners Inc acquired a new position in shares of Cellebrite DI in the fourth quarter valued at approximately $85,000. Finally, NewEdge Advisors LLC grew its holdings in Cellebrite DI by 600.7% during the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after acquiring an additional 3,352 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company's stock.

Analyst Ratings Changes

Several brokerages recently commented on CLBT. Lake Street Capital reduced their price objective on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research note on Friday, August 15th. Needham & Company LLC reduced their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, August 14th. JPMorgan Chase & Co. lowered their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Finally, Wall Street Zen upgraded shares of Cellebrite DI from a "hold" rating to a "buy" rating in a report on Saturday, August 16th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $22.40.

Cellebrite DI Stock Up 1.1%

Shares of CLBT traded up $0.18 during midday trading on Friday, hitting $16.55. The company's stock had a trading volume of 772,109 shares, compared to its average volume of 1,690,919. The stock has a market capitalization of $3.96 billion, a price-to-earnings ratio of -21.74, a price-to-earnings-growth ratio of 3.00 and a beta of 1.28. Cellebrite DI Ltd. has a one year low of $13.10 and a one year high of $26.30. The company's fifty day simple moving average is $15.01 and its two-hundred day simple moving average is $17.06.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.01. The company had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The firm's quarterly revenue was up 18.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.